Pipeline—creating tomorrow's vaccines today

The world urgently needs new tools to help solve some of our greatest infectious disease challenges. At Novavax, our passion is helping to protect the health of people everywhere, so we are working to build a strong first line of defense against infectious diseases like COVID, influenza and malaria worldwide.

Novavax continues to optimize preclinical candidates, including a new approach to H5N1 bird flu vaccination. In addition, we are seeking to expand our core technology to new targets and novel applications including mucosal vaccination and high-density nanoparticles. We continue to evaluate the potential of Matrix-M^TM to augment immune responses to new and existing vaccines, including marketed products. We are conducting a prioritization review of our preclinical candidates to inform future early-stage clinical study investments to advance Novavax's product pipeline.

Our pipeline

Novavax aims to develop innovative vaccines that may help improve lives and fight infectious diseases around the world. The table below lists our selected research and development priorities.

Our Matrix-M adjuvant technology

Matrix-M adjuvant

Investigational vaccines listed below with the Matrix-M symbol have been developed with the Matrix-M adjuvant.

Learn more about our technology platform

Vaccines in Novavax Pipeline and Status
Therapeutic area	Candidate	Adjuvant Technology	Phase of trial				Authorized use
			Preclinical	Phase 1	Phase 2	Phase 3
Novavax Clinical/Commercial Stage
Respiratory diseases COVID-19	Novavax COVID-19 vaccine	Matrix-M™ adjuvant					Authorized¹
Novavax Clinical Stage
Respiratory diseases COVID-19 + seasonal influenza	COVID-influenza combination (CIC) vaccine	Matrix-M™ adjuvant			Phase 2
Novavax Clinical Stage
Respiratory diseases Seasonal influenza	Influenza vaccine (Older Adults)	Matrix-M™ adjuvant			Phase 2
Developed and distributed by Oxford University and Serum Institute of India, using licensed Matrix-M technology
Parasitic diseases Malaria	R21/Matrix-M	Matrix-M™ adjuvant					Authorized²

Respiratory diseases

COVID-19

Novavax COVID-19 vaccine

Authorized¹

Matrix-M™ adjuvant

Novavax Clinical/Commercial Stage

Respiratory diseases

COVID-19 + seasonal influenza

COVID-influenza combination (CIC) vaccine

Phase 2

Matrix-M™ adjuvant

Novavax Clinical Stage

Respiratory diseases

Seasonal influenza

Influenza vaccine (Older Adults)

Phase 2

Matrix-M™ adjuvant

Novavax Clinical Stage

Parasitic diseases

Malaria

R21/Matrix-M

Authorized²

Matrix-M™ adjuvant

Developed and distributed by Oxford University and Serum Institute of India, using licensed Matrix-M technology

¹Authorized in select geographies under trade names Novavax COVID-19 Vaccine, Adjuvanted; Covovax™; and Nuvaxovid™, authorized in the U.S. under trade name, Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula); and authorized in the EU under the trade name Nuvaxovid XBB.1.5. Authorization information can be found by country at https://novavaxcovidvaccine.com.

²Authorized in Ghana, Nigeria, Central African Republic, Côte d'Ivoire and Burkina Faso; Commercialized by Serum Institute of India and granted prequalification by the WHO.